King buys Canadian rights to market EpiPen
This article was originally published in Clinica
Bristol, Tennessee-based King Pharmaceuticals has acquired from distributor Allerex Laboratory exclusive rights to market and sell EpiPen, the epinephrine-filled auto-injector used as emergency treatment for severe anaphylaxis, in Canada.
You may also be interested in...
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.
The AAM has insisted that the US Supreme Court should uphold the inter partes review framework, in an amicus brief filed as part of litigation that potentially threatens hundreds of IPR decisions.